Knowledge is power when buying durian’, Musang King now RM20-30/kg

 

Tang (left) showing Mat Suaid (second right) and agriculture department staff the durians at his Gertak Sanggul orchard. The opened fruits are Black Thorn (right) and Musang King. — Photos: CHAN BOON KAI/The Star

BALIK Pulau durian farmers take immense pride in the varieties grown for generations in Penang.

They include the Ang Hae (Red Prawn), Hor Lor, Ang Bak and XO varieties of the fruit.

In order to avoid disappointment and paying a premium price for sub-par fruit, Southwest District Agriculture Department officer Mat Suaid Sapiyin advised durian lovers to learn to recognise the physical traits rather than trusting a seller’s claims.

“Take the much sought-after Black Thorn (Or Chi) for instance. “The premium variety is typically round and weighs between 1.5kg and 2.5kg.

“It has a prominent dot at the base resembling a thorn,” he said.

Mat Suaid encouraged consumers to familiarise themselves with the main clones from the area and verify the orchard’s location.

The Black Thorn (right) has a prominent dot at the base resembling a thorn, while Musang King (left) has a flat crown and vertical seams running down to a distinct five-point star at the base.

“Do not to be swayed by irresponsible traders or middlemen when buying the fruit.

“Choose reputable or registered farmers, check the stem, aroma and ripeness of the fruit, and ask for documentation, especially for the Geographical Indication (GI) of premium varieties.”

Mat Suaid said Penang was still in the process of implementing Mi-Trace, a QR code system developed with Mimos Bhd to help combat fraud and misrepresentation.

Farmers are also registered with the Intellectual Property Corporation of Malaysia (MyIPO) and district agriculture office and have acquired Malaysian Good Agricultural Practices (myGAP) certification to strengthen source verification of their fruits, he added.

Orchard owner Tang Boon Ley, 60, said there was also a need for processing platforms or collection centres with blast freezers, cold storage, and downstream processing facilities.

He said it could be a long-term solution for surplus durian.

“Now may be the best time for people to eat premium durian at a lower price, but eventually something must be done.”

He said such infrastructure, coupled with cooperative models, would help stabilise prices, reduce wastage and allow growers to tap into value-added products such as durian paste, ice-cream and confectionery.

Musang King now RM20-30/kg

Going easy: Tang (left) showing Fahmirudin (second from left) and other officers a particular type of durian at his orchard in Getak Sanggul, Penang. In the foreground are Musang King (left) and Or Chi durians. — CHAN BOON KAI/The Star

GEORGE TOWN: The prices have dropped but many consumers are not biting.

Musang King durian is now selling at lower prices due to oversupply but traders are not seeing roaring sales yet.

Durian orchard owner Tang Boon Ley believes this is partly due to families prioritising school expenses as the new term begins on Monday.

“Durians are not a priority for them at the moment,” he said in an interview.

Tang said Musang King is now priced between RM20 and RM30 per kg, a sharp drop from RM60 to RM80 per kg during the previous durian season from May to August.

Furthermore, he said weaker consumer spending was also due to the fact that the fruit is being sold outside the main durian season.

“This is considered a ‘bonus’ season,” he said.

Tang said the growing number of Musang King orchard owners had led to an oversupply, further driving prices down. At the same time, newer durian varieties have also entered the market, intensifying competition, he said.

“For durian lovers, this is the best time to enjoy affordable Musang King. This is expected to last until Chinese New Year.

“Prices are likely to return to normal when the new durian season begins in May,” he said.

Once the undisputed favourite among durian fans, Mu­­sang King now faces stiff competition from other varieties such as Or Chi (Black Thorn) and Tupai King.

Penang Agriculture Department assistant agricultural officer Fahmirudin Zainol Abidin said wholesale prices for Musang King have dropped significantly, as processing facilities struggle to cope with the surplus.

He said the price decline was driven by simultaneous harvesting in Penang, Perak, Pahang and Johor, with overall production estimated to have tripled.

“This is not a demand issue but a capacity problem. Excess supply has pushed prices down,” he said.

Penang has two durian seasons annually, with the harvest typically peaking in June and July.

A smaller, less predictable harvest can occur from November to January.

In identifying genuine durians from Balik Pulau, particularly Ang Hae (Red Prawn), Fahmirudin said the variety can be determined through subtle physical traits.

“Local Ang Hae typically has a slightly greyish husk and a distinctive fruit shape that differs from similarly named varieties found in Perak, Pahang or Johor.

“Or Chi, on the other hand, is recognised by its rounder shape, widely spaced thorns and a pronounced star-shaped base.

“These are the features growers use to distinguish it from Musang King,” he said.

Under­stand­ing pop­u­lar weight-loss drugs

 

The class of drugs known as GLP-1 receptor agon­ists have become renowned for their effects in help­ing weight loss.

MALAYSIA is the most obese and over­weight nation in Asean.

Over­weight adults form 32.6% of the pop­u­la­tion, while obese adults form another 21.8%, adding up to 54.4% of the pop­u­la­tion.

Not only that, about 29.8% of chil­dren are obese or over­weight.

In addi­tion, about 21% of Malay­si­ans are dia­betic, of which 80% are obese or over­weight.

The Health Min­istry (MOH) is intro­du­cing glu­ca­gon-like pep­tide 1 (GLP-1) medi­cines for “vul­ner­able groups” this year.

Who the vul­ner­able groups are is unclear.

However, it behoves every­one to ensure that patient safety is not com­prom­ised by the use of GLP-1 medi­cines.

How they work

GLP-1 medi­cines are receptor agon­ists that mimic the GLP-1 hor­mone that is nat­ur­ally released in the gastrointest­inal tract in response to eat­ing.

When a per­son eats, the digest­ive sys­tem breaks down car­bo­hydrates into simple sug­ars that enter the blood­stream.

GLP-1 stim­u­lates the release of insulin from the pan­creas.

Insulin, a pan­cre­atic hor­mone, helps get gluc­ose out of the blood­stream into the body’s cells, where it is used for nour­ish­ment and energy.

In dia­betes, the body’s cells are res­ist­ant to insulin, do not pro­duce suf­fi­cient insulin, or both. GLP-I medi­cines stim­u­late the pan­creas to release insulin and reduce the release of glu­ca­gon.

Both insulin and glu­ca­gon con­trol the blood gluc­ose levels in humans, includ­ing type II dia­bet­ics.

GLP-1 medi­cines also act on the brain to reduce hun­ger and delay empty­ing of the stom­ach.

These drugs are used in the man­age­ment of type II dia­betes, and in some instances, obesity in non-dia­bet­ics.

They reduce food crav­ings, increase full­ness (sati­ety), slow diges­tion and can help con­trol blood gluc­ose.

GLP-1 medi­cines were licensed for dia­betes man­age­ment in Malay­sia in 2007, and was approved for obesity man­age­ment in 2019.

As of 2025, there are more than 30 GLP-1 medi­cines registered.

There are dif­fer­ent types of GLP-1 medi­cines.

Some are injec­tions and oth­ers

are tab­lets. Some are licensed for dia­betes, and oth­ers are licensed for weight-loss man­age­ment, or to treat the over­weight with weight-related health prob­lems.

Side effects

Like all medi­cines, GLP-1 agon­ists have side effects.

The com­mon ones are gastrointest­inal, i.e. nausea, vomit­ing and diarrhoea, which are usu­ally mild to mod­er­ate, and of short dur­a­tion.

Some­times, these side effects can be ser­i­ous, lead­ing to severe dehyd­ra­tion that requires hos­pit­al­isa­tion.

A ser­i­ous, but uncom­mon, side effect is pan­cre­at­itis.

Any­one on GLP-1 medi­cine with severe abdom­inal pain that radi­ates to the back should seek imme­di­ate med­ical atten­tion.

Other ser­i­ous, but uncom­mon, side effects include: > Gast­ro­paresis – where move­ment of food out of the stom­ach is slowed or stopped > Bowel obstruc­tion – a block­age that keeps food from passing through the intest­ines > Gall­stone attacks, and

> Bile duct block­age.

Rapid weight loss can cause facial changes that include a hol­lowed look, wrinkles, sunken eyes, sag­ging jowls around the jaws and neck, and changes in the size of the lips, cheek and chin.

This is com­monly called the “Ozempic” face, after the brand name of one of the more wellknown GLP-1 med­ic­a­tions.

If the weight loss is less rapid, the facial changes would not be so obvi­ous.

Sig­ni­fic­ant facial changes can be treated by plastic sur­gery.

The sexual side effects of GLP-1 medi­cines involve both poten­tial improve­ments (through weight loss and hor­monal optim­isa­tion), and declines in libido or arousal, which is vari­able across sex and indi­vidual pro­files.

A full list of the known side effects is found in the product inform­a­tion of the indi­vidual GLP-1 medi­cine.

A recent review repor­ted that

GLP-1 medi­cines may have little or no effect on obesity-related can­cers, i.e. thyroid, breast, pan­cre­atic or kid­ney.

They may also have little or no effect on colorectal, oeso­pha­geal, liver, gall­blad­der, ovarian or endo­metrial can­cer; mul­tiple myel­oma; or men­in­gioma (low cer­tainty).

The effect on gast­ric can­cer was very uncer­tain.

Cur­rent data does not sup­port a causal asso­ci­ation between GLP-1 medi­cines and depres­sion, sui­cidal ideation and sui­cide.

Pre­cau­tions

GLP-1 medi­cines should not be taken in preg­nancy, by those who are try­ing to get preg­nant or by those who are breast­feed­ing, because there is insuf­fi­cient data on the drugs’ safety in such situ­ations.

In the case of those try­ing to get preg­nant, the num­ber of months the GLP-1 medi­cine should be stopped prior to attempt­ing con­cep­tion var­ies, depend­ing on the indi­vidual medi­cine.

Oral con­tra­cept­ive users should use bar­rier con­tra­cep­tion, e.g. con­doms, for four weeks after start­ing GLP-1 medi­cines, and for four weeks after any increase in dose.

The reason is that the GLP-1 medi­cines may reduce the effect­ive­ness of oral con­tra­cept­ives in the over­weight or obese.

Altern­at­ively, a non-oral form of con­tra­cep­tion, e.g. an intrauter­ine con­tra­cept­ive device (IUCD) or implant, which are not as affected by GLP-1 medi­cines, can be used.

Prior to a sur­gical pro­ced­ure, the patient should inform their attend­ing doc­tors and nurses if they are tak­ing GLP-1 medi­cines.

This is because these drugs slow the empty­ing of the stom­ach, thereby increas­ing the like­li­hood of stom­ach con­tents enter­ing the air­ways and lungs dur­ing the sur­gical pro­ced­ure while under gen­eral anaes­thesia or sed­a­tion.

This means that modi­fic­a­tion of the pre-pro­ced­ure instruc­tion and anaes­thetic tech­nique may be required.

The attend­ing doc­tor(s) will also advise on the tak­ing of pre­scribed medi­cine(s).

Be aware

It is vital to remem­ber that GLP-1 medi­cines are Group B pois­ons, i.e. they require a doc­tor’s pre­scrip­tion.

It is illegal to pur­chase them over the counter or through unli­censed online sellers.

Self-med­ic­a­tion is poten­tially dan­ger­ous – a mes­sage that applies not only to GLP-1 medi­cines, but also many pre­scrip­tion medi­cines.

Reports of mis­use of GLP-1 medi­cines for cos­metic weightloss pur­poses are of con­cern.

The global demand for GLP-1 medi­cines has led to the spread of false and sub­stand­ard products, with severe risks to patient safety, eco­nomic impacts and erosion of pub­lic trust.

These coun­ter­feit medi­cines often con­tain incor­rect dosages, harm­ful ingredi­ents or lack the act­ive GLP-1 entirely, lead­ing to inef­fect­ive treat­ment and poten­tially life-threat­en­ing com­plic­a­tions such as hyper/hypoglycaemia and car­di­ovas­cu­lar (heart) issues.

The eco­nomic impacts are con­sid­er­able, with sub­stan­tial costs incurred in man­aging com­plic­a­tions that include hos­pit­al­isa­tion and increased mon­it­or­ing efforts.

Guidelines for doc­tors The frame­work for GLP-1 use in Malay­sia is found in the

Clin­ical Prac­tice Guidelines for the Man­age­ment of Obesity.

GLP-1 medi­cines are recom­men­ded for adults with a body mass index (BMI) more than 30kg/m2 or a BMI more than 27kg/m2 with one weight-related con­cur­rent ill­ness, e.g. hyper­ten­sion (high blood pres­sure), type II dia­betes or dys­lip­id­aemia (abnor­mal fat levels).

The World Health Organ­iz­a­tion (WHO) launched its guideline on the use of GLP-1 ther­apies for the treat­ment of obesity in adults on Dec 1, 2025.

The good prac­tice state­ments in the guideline are:

> “Obesity is a chronic com­plex dis­ease that requires lifelong care begin­ning with clin­ical assess­ment and early dia­gnosis.

“Once dia­gnosed, indi­vidu­als should have access to com­pre­hens­ive chronic care pro­grammes offer­ing sus­tained beha­vi­oural and life­style inter­ven­tions.

“When appro­pri­ate, phar­ma­co­lo­gical, sur­gical or other thera­peutic options may be used to sup­port effect­ive dis­ease man­age­ment.

“In par­al­lel, care should address the pre­ven­tion and treat­ment of obesity-related com­plic­a­tions and comor­bid­it­ies.”

> “In adults liv­ing with obesity, GLP-1 receptor agon­ists or GIP/ GLP-1 dual agon­ists may be used as long-term treat­ment for obesity.”

> “People liv­ing with obesity should receive con­text-appro­pri­ate coun­selling on beha­vi­oural and life­style changes – includ­ing, but not lim­ited to, phys­ical activ­ity and healthy diet­ary prac­tices – as an ini­tial step toward more struc­tured beha­vi­oural inter­ven­tions.

“For indi­vidu­als who are pre­scribed GLP-1 receptor agon­ists or GIP/GLP-1 dual agon­ists, coun­selling on beha­vi­oural and life­style changes should be provided as a first step to intens­ive beha­vi­oural ther­apy to amp­lify and sup­port optimal health out­comes.

> “In adults liv­ing with obesity who are pre­scribed GLP-1 receptor agon­ists or GIP/GLP-1 dual agon­ists, intens­ive beha­vi­oural ther­apy may be provided as a co-inter­ven­tion within a com­pre­hens­ive mul­timodal clin­ical algorithm.”

The jury is out on whether the WHO good prac­tice state­ments will be imple­men­ted in toto or par­tially in MOH facil­it­ies.

Part of a strategy

Recog­nising that medi­cines by them­selves would not by them­selves address the global obesity chal­lenge, the WHO recom­men­ded a com­pre­hens­ive strategy based on:

> “Cre­at­ing health­ier envir­on­ments through robust pop­u­la­tion-level policies to pro­mote health and pre­vent obesity. > “Pro­tect­ing indi­vidu­als at high risk of devel­op­ing obesity and related comor­bid­it­ies through tar­geted screen­ing and struc­tured early inter­ven­tions. > “Ensur­ing access to lifelong per­son-centred care.”

The safe use of GLP-1 medi­cines requires reg­u­lated dis­tri­bu­tion and pre­scrip­tion by doc­tors, strong over­sight, patient edu­ca­tion and stake­hold­ers’ cooper­a­tion to ensure that pub­lic health is pro­tec­ted.

Dr Milton Lum is a past pres­id­ent of the Fed­er­a­tion of Private Med­ical Prac­ti­tion­ers Asso­ci­ations and the Malay­sian Med­ical Asso­ci­ation. For more inform­a­tion, email star­health@the­star.com.my. The views expressed do not rep­res­ent that of organ­isa­tions that the writer is asso­ci­ated with. The inform­a­tion provided is for edu­ca­tional and com­mu­nic­a­tion pur­poses only, and it should not be con­strued as per­sonal med­ical advice. Inform­a­tion pub­lished in this art­icle is not inten­ded to replace, sup­plant or aug­ment a con­sulta­tion with a health pro­fes­sional regard­ing the reader’s own med­ical care. The Star dis­claims all respons­ib­il­ity for any losses, dam­age to prop­erty or per­sonal injury suffered dir­ectly or indir­ectly from reli­ance on such inform­a­tion.

The doc­tor says by DR MILTON LUM 18 Jan 2026

Mandarin, a good lesson for the future

 

SHAH ALAM: It’s a common wish list for non-Chinese parents who send their children to Chinese schools.

“I want her to learn and converse in Mandarin,” said Megat Azri Hakim Sazali of his daughter Puteri Humaira Rose, seven, who is enrolled at SJK(C) Ladang Regent, Elmina, here.

In fact, he had been preparing her for the past three years by sending her to a Mandarin-medium kindergarten.

“This means that she would not face a ‘culture shock’ when attending school.

“The kindergarten prepared her well. She was given a lot of homework even then!”

Exam review: Fadhlina says the ministry will consider parents’ views on the abolition of UPSR and PT3, as well as Classroom-Based Assessment performance levels, in its review on reinstating the two national exams. — Bernama

Another parent, Mohd Azwan Mohd Noor, said it was important for him that his three daughters – nine-year-old twins and an eight-year-old – could converse in Mandarin.

“China is now a powerful economy in the world. Being able to converse in Mandarin would be an advantage,” he said.

Another important factor is that Chinese schools attract a mix of students from different races, he added.

For Shakilla Khoriri, the chance to educate her daughter in Man­darin was too good to pass up.

She wanted her daughter Nurul Ameena Sofia Muhd Hafizudin, seven, to embrace the discipline practised in Chinese schools.

“Children nowadays are growing up in a different world, one where if we as parents are not careful, they will get ‘lost’,” she said.

First-day nerves: A pupil crying on the first day of school at SJK(C) Ladang Regent, Elmina. — IZZRAFIQ ALIAS/The Star

“I want my daughter to interact and pick up the good habits of the students in Chinese schools.

“At the same time, she would be able to converse in Mandarin with them.”

Shakilla had earlier intended to send her daughter to a private school, which was further away from their home.

“But when I heard that a Chinese school was opening up here, I immediately enrolled (her),” she said.

Another parent, Krishnaveni Janardanan, said it was her husband who suggested that their daughter attend a Chinese school.

She said the ability to speak fluent Mandarin opens up nume­rous opportunities in today’s working world.

“Lucky for us, the government had opened a Chinese school here in Elmina where I live,” she said.

Happy tummies: Pupils posing as they finish their breakfast during recess at SJK(C) Ladang Regent, Elmina. — IZZRAFIQ ALIAS/The Star

For these children, their first day of school saw them attending Year One classes where the tea­chers gave out instructions purely in Mandarin.

But they seemed to have no trouble following the classes, as most of them had been learning Mandarin since kindergarten.

Yesterday marked not only the first day of the 2026 school year but also the launch of SJK(C) Ladang Regent, Elmina.

Its board of directors chairman Datuk Dr Azman Ching said there are around 300 students enrolled at the school, which was reloca­ted from Gemencheh, Negri Sembilan.

Meanwhile, Education Minister Fadhlina Sidek, who was present at the launch, said all stakehol­ders will soon be required to sign the Child Protection Policy as a pledge to safeguard children.

“We are not going to compromise on this matter. It is our shared responsibility to ensure our schools are safe and our children are protected,” she said.

The ministry will also be distributing a Safe Schools book to students and parents, she added.

Fadhlina also said the ministry is taking into account all views from parents regarding the abolish­ment of the Ujian Pen­taksiran Sekolah Rendah (UPSR) and Penilaian Tingkatan Tiga (PT3) examinations, as well as the performance levels for the Classroom-Based Assessments, when they begin reviewing the reinstatement of the two national examinations.

“The review will be held this year and we will announce (the results) as soon as possible,” she said.

Last week, the minister said that she had reactivated the National Education Advisory Council to study the need to revive the two examinations.

UPSR was abolished in 2021, followed by PT3 in 2022, and both were replaced with School-Based Assessment.

More than five million students began the 2026 school year nationwide since Sunday.

China says it cannot accept countries acting as 'world judge' after US captures Maduro; China's Strategic Victory in Venezuela: The End of US Dominance?

"> 

US Department of Justice federal officers stand guard outside the Metropolitan Detention Center, where ousted Venezuelan President Nicolas Maduro is being held, in the Brooklyn borough of New York City, on January 4, 2026. Venezuela's deposed president Nicolas Maduro is scheduled to appear before a federal judge in New York at noon on January 5, to be formally notified about the charges against him, the court said. Maduro and his wife, Cilia Flores, were seized by US forces during a pre-dawn raid on January 3 in Caracas and brought to New York to face charges of "narcoterrorism" tied to alleged trafficking of tons of cocaine into the United States. - AFP

BEIJING: Chinese Foreign Minister Wang Yi said Beijing cannot accept any country acting as the "world's judge" after the United States captured Venezuela's President Nicolas Maduro.

"We have never believed that any country can act as ‌the world's police, nor do we accept that any nation can ⁠claim to be the world's judge," Wang told his Pakistani counterpart Ishaq Dar during a meeting in Beijing on Sunday (Jan 4), referring to "sudden developments in ​Venezuela" without directly mentioning the US.

"The sovereignty and security of all countries should be fully protected under international law," China's top diplomat added, in his first remarks since images of the 63-year-old Maduro blindfolded and handcuffed on Saturday stunned Venezuelans.

Maduro is in a New York detention centre awaiting a Monday court appearance on drug charges.

Beijing has ambition to become a diplomatic heavyweight, a goal it articulated most clearly after brokering a surprise rapprochement between ‍Saudi Arabia and Iran ⁠in 2023, pledging ‍to "play ​a constructive role in global hotspot issues."

Analysts say Beijing's success in going ⁠toe-to-toe with the US in trade negotiations has only reinforced China's confidence.

However, President Donald Trump's assertion that the US will oversee Venezuela's government for the time being poses a stern test to the "all-weather comprehensive strategic partnership" Beijing and Caracas ‍struck in 2023, marking almost 50 years ‍of diplomatic ties.

"It was a big blow to China, we wanted to look like a dependable friend ‌to Venezuela," said a Chinese government official briefed on a meeting between Maduro and China's special representative for Latin American ⁠and Caribbean affairs, Qiu Xiaoqi, hours before his capture.

Maduro's son visited China's top-ranking Peking University in 2024, where he enrolled in 2016, they said, adding they were unsure whether he would return despite years of diplomatic engagement with Caracas ⁠around his education and ties to China.

The world's second-largest economy has provided Venezuela with an economic lifeline since the US and its allies ramped up sanctions in 2017, purchasing roughly US$1.6  billion worth of goods in 2024, the most recent full-year data available.

Almost half of China's purchases were crude oil, customs data ‍shows, while its state-owned oil giants had invested around US$4.6 billion in Venezuela by 2018, according ⁠to data from the American Enterprise Institute think tank, which tracks Chinese overseas corporate investment. - Reuters

Related:

GT investigates: Unveiling US' long-standing geopolitical, economic and ideological intrigues in Latin America

China racing ahead in Britain

 

Keith’s BYD car dealership in Leeds, England. In the last year, Chinese-made vehicles have doubled their share of new car registrations in Britain. — Owen Richards/The New York Times

ON a recent Monday in Leeds, Dougal Keith drove a Chinese-made BYD Seal Excellence out of his dealership and hit the accelerator.

The car can reach 100kph in 3.8 seconds – a key selling point – and comes with a £48,000 price tag, roughly 20% cheaper than a top-range Tesla Model 3.

Keith, a car salesman for more than 40 years, said customers were sceptical of buying Chinese vehicles when he opened a showroom for BYD in 2023.

Now, he runs six dealerships devoted to the brand.

“Some people think because it’s Chinese it’s made cheaply,” he said. “But then I ask, ‘Where do you think your iphone is assembled?’”

Chinese cars are gaining ground in Britain for a mix of reasons.

There are no steep tariffs on Chinese EVS – unlike in the EU or the US – allowing lower prices. British buyers are also less brand-loyal, with no major domestic mass-market automaker to defend.

Roughly a dozen Chinese brands, including BYD, Chery and Geely, made up 13% of new car registrations in Britain in November, double their share a year ago, according to the Society of Motor Manufacturers and Traders.

“The pace is like nothing the market has ever seen,” said Ian Plummer, chief commercial officer of Autotrader.

BYD and Chery, selling Jaecoo and Omoda models, are gaining market share five or six times faster than Tesla a decade ago or South Korea’s Kia in the 1990s.

Britain’s domestic auto industry has been shrinking, producing about 600,000 cars in 2025, roughly half of the output at the end of the last decade.

Major producers include Nissan, Jaguar Land Rover and Mini.

Meanwhile, China is now the world’s largest car exporter and leads in EV production, exporting to markets from Mexico to South Africa.

Chinese automakers have mastered shifting regulations and consumer demand, particularly for hybrids.

Beijing encourages exports to manage domestic overcapacity, sometimes leading to heavy losses and triggering pushback in Western countries.

The US has imposed 100% tariffs on Chinese EVS, the EU up to 45%, while Britain charges 10% on all imported cars.

About two million new cars are sold in Britain each year.

Since 2019, the number of brands registering sales has nearly doubled to over 70.

No single brand commands loyalty like Volkswagen in Germany or Renault in France, giving newcomers room to grow.

Chinese brands first gained a foothold with SAIC Motor’s acquisition of MG.

Production gradually moved to China, and the UK MG factory closed in 2016.

MG now accounts for over 4% of new registrations – the largest share for a Chinese-owned brand – while BYD holds just over 2%, similar to Tesla.

Keith sold his first car in 1980 at 16 and later expanded his family business.

By the early 2020s, he noticed BYD and,

“Some people think because it’s Chinese it’s made cheaply. But then I ask, ‘Where do you think your iphone is assembled?’”

Dougal Keith

with other independent dealers, secured one of the first UK franchises.

Initially, sales were slow, with only an all-electric model available.

As more models arrived, particularly plug-in hybrids, sales surged.

Dealers highlighted tech features: rotatable touch screens, wireless chargers, voice controls, even karaoke.

“Customers are beginning to understand it’s not a budget brand,” said Fozia Siddique, who has worked with BYD since the Leeds showroom opened.

She recently sold a BYD plug-in hybrid SUV to Steve Vine, 55, who drives more than 480km from Leeds to Cornwall and wanted a long-range EV.

Roger Lyons, 60, in Derbyshire, chose a £48,000 BYD Seal Excellence after testing Audi, Hyundai and Porsche models.

“It’s almost as nice to drive as a Porsche, and it’s got more toys than any of the others,” he said, adding that switching to electric would help cut fuel costs.

Encouraged by the success of BYD, Keith opened two more dealerships selling Changan vehicles.

His group, which runs 28 dealerships selling global brands, expects £500mil in sales for 2025, over 50% higher than 2024.

In September, the Leeds BYD showroom outsold all his other local locations.

“It’s pretty good going for a brand that two years ago nobody had heard of,” he said. — ©2026 The New York Times Company

By ESHE NELSON This article originally appeared in The New York Times

3 Jan 2026